Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification

被引:0
|
作者
Song, Byeong Geun [1 ]
Kim, Aryoung [1 ]
Goh, Myung Ji [1 ]
Kang, Wonseok [1 ]
Gwak, Geum-Youn [1 ]
Paik, Yong-Han [1 ]
Choi, Moon Seok [1 ]
Lee, Joon Hyeok [1 ]
Sinn, Dong Hyun [1 ]
机构
[1] Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Sch Med, Seoul, South Korea
关键词
Steatotic liver disease; Metabolic dysfunction-associated steatotic liver disease; Nonalcoholic fatty liver disease; Metabolic dysfunction-associated fatty liver disease; Hepatocellular carcinoma; CONSENSUS STATEMENT; METABOLIC SYNDROME; CANCER; NAFLD; MORTALITY; FIBROSIS; ALCOHOL; OBESITY; HCC;
D O I
10.1159/000538301
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Steatotic liver disease (SLD) is a new overarching term proposed to replace nonalcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease. Subclassification includes metabolic dysfunction-associated SLD (MASLD), MASLD with increased alcohol intake (MetALD), and cryptogenic SLD. This study aimed to investigate whether SLD and its subclassification could stratify hepatocellular carcinoma (HCC) risk. Methods: A cohort of 85,119 adults without viral hepatitis or heavy alcohol intake was analyzed for the risk of HCC according to SLD and its subclassification. The fibrosis-4 (FIB-4) index was used to estimate the degree of liver fibrosis. Results: During a median follow-up of 11.9 years, HCC was diagnosed in 123 individuals. The incidence rate of HCC per 1,000 person-years was higher in individuals with SLD than in those without SLD (0.197 vs. 0.071, p < 0.001), with an adjusted hazard ratio of 2.02 (95% confidence interval: 1.40-2.92). The HCC incidence rate per 1,000 person-years was 0, 0.180, and 0.648 for cryptogenic SLD, MASLD, and MetALD, respectively. When participants with SLD was further stratified by the FIB-4 index, the HCC incidence rate per 1,000 person-years was 0.074 for SLD with FIB-4 < 1.3 and 0.673 for SLD with FIB-4 >= 1.3. Of note, HCC risk was substantially high (HCC incidence rate: 1.847 per 1,000 person-years) for MetALD with FIB-4 >= 1.3. Conclusions: HCC risk was different by SLD and its subclassification. The utilization of SLD and its subclassification can aid in stratifying HCC risk and facilitate the identification of individuals requiring interventions to mitigate the risk of HCC.<br /> (c) 2024 The Author(s).Published by S. Karger AG, Basel
引用
收藏
页码:561 / 571
页数:11
相关论文
共 50 条
  • [21] A COMPARATIVE VALIDATION OF CLINICAL PREDICTION SCORES FOR HEPATOCELLULAR CARCINOMA IN STEATOTIC LIVER DISEASE WITHOUT CIRRHOSIS
    Mezzacappa, Catherine
    Tate, Janet
    Taddei, Tamar
    Justice, Amy
    HEPATOLOGY, 2024, 80
  • [22] DEEP LEARNING PREDICTS HEPATOCELLULAR CARCINOMA DEVELOPMENT IN STEATOTIC LIVER DISEASE USING DIGITAL PATHOLOGY
    Nakatsuka, Takuma
    Tateishi, Ryosuke
    Sato, Masaya
    Irie, Rie
    Tsujikawa, Hanako
    Sumida, Yoshio
    Yoneda, Masashi
    Akuta, Norio
    Kawaguchi, Takumi
    Takahashi, Hirokazu
    Eguchi, Yuichiro
    Seko, Yuya
    Itoh, Yoshito
    Murakami, Eisuke
    Chayama, Kazuaki
    Taniai, Makiko
    Tokushige, Katsutoshi
    Okanoue, Takeshi
    Sakamoto, Michiie
    Fujishiro, Mitsuhiro
    Koike, Kazuhiko
    HEPATOLOGY, 2024, 80 : S555 - S556
  • [23] Significance of liver resection for intermediate stage hepatocellular carcinoma according to subclassification
    Yamamoto, Masateru
    Kobayashi, Tsuyoshi
    Hashimoto, Masakazu
    Kuroda, Shintaro
    Kawaoka, Tomokazu
    Aikata, Hiroshi
    Chayama, Kazuaki
    Ohdan, Hideki
    BMC CANCER, 2021, 21 (01)
  • [24] Modifiable Risk Factors for Hepatocellular Carcinoma in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis
    Xiao, Shiyu
    Liu, Ya
    Fu, Xiliang
    Chen, Tong
    Xie, Wenhui
    AMERICAN JOURNAL OF MEDICINE, 2024, 137 (11):
  • [25] Phenotypes of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma
    Esteban, Jesus Rivera-
    Munoz-Martinez, Sergio
    Higuera, Monica
    Sena, Elena
    Bermudez-Ramos, Maria
    Banares, Juan
    Martinez-Gomez, Maria
    Cusido, M. Serra
    Jimenez-Masip, Alba
    Francque, Sven M.
    Tacke, Frank
    Minguez, Beatriz
    Pericas, Juan M.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (09)
  • [26] Long-term Risks of Cirrhosis and Hepatocellular Carcinoma Across Steatotic Liver Disease Subtypes
    Chen, Yi-Ting
    Chen, Tzu-, I
    Yang, Tsai-Hsuan
    Yin, Szu-Ching
    Lu, Sheng-Nan
    Liu, Xia-Rong
    Gao, Yun-Zheng
    Lin, Chih-Jo
    Huang, Chia-Wei
    Huang, Jee-Fu
    Yeh, Ming-Lun
    Huang, Chung-Feng
    Dai, Chia-Yen
    Chuang, Wan-Long
    Yang, Hwai-, I
    Yu, Ming-Lung
    Lee, Mei-Hsuan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (11): : 2241 - 2250
  • [27] Exploring the Role of Metabolic Hyperferritinaemia (MHF) in Steatotic Liver Disease (SLD) and Hepatocellular Carcinoma (HCC)
    Anastasopoulos, Nikolaos-Andreas
    Barbouti, Alexandra
    Goussia, Anna C.
    Christodoulou, Dimitrios K.
    Glantzounis, Georgios K.
    CANCERS, 2025, 17 (05)
  • [28] A male mouse model for metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma
    Jeong, Byung-Kwan
    Choi, Won-Il
    Choi, Wonsuk
    Moon, Jieun
    Lee, Won Hee
    Choi, Chan
    Choi, In Young
    Lee, Sang-Hyun
    Kim, Jung Kuk
    Ju, Young Seok
    Kim, Pilhan
    Moon, Young-Ah
    Park, Jun Yong
    Kim, Hail
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [29] NONALCOOLIC FATTY LIVER DISEASE AND ITS COMPLICATIONS. ASSESING POPULATION AT RISK FOR HEPATOCELLULAR CARCINOMA
    Timofte, Daniel
    Ionescu, Lidia
    Danila, Radu
    Sangeap, Ana-Maria
    Trifan, Anca
    Drug, Vasile
    Livadariu, Roxana Maria
    OBESITY SURGERY, 2015, 25 : S307 - S308
  • [30] Metabolic dysfunction-associated steatotic liver disease: a key factor in hepatocellular carcinoma therapy response
    Llamoza-Torres, Camilo Julio
    Fuentes-Pardo, Maria
    Ramos-Molina, Bruno
    METABOLISM AND TARGET ORGAN DAMAGE, 2024, 4 (04):